The microbiota intestinal is made up of a series of microorganisms that houses our intestine. Until a few years ago it was thought that all these microorganisms did was take advantage of us, and even, predisposed us to have diseases.
Now we know that this is not the case, quite the opposite. These bacteria produce certain metabolites which, once introduced into the bloodstream, affect the functioning of organs not related to thedigestive systemlike the heart, lungs, and even the central nervous system.
And they also influence obesity. In a study carried out with germ-free rats, which were inoculated with intestinal flora from obese people, and from lean people, it was observed that, maintaining the conditions of feeding and movement in both groups equally, rats with stools from obese people got fat and those inoculated with feces from thin individuals, were kept at their weight.
Given these scientific evidences, the development of probiotic drugs that support our intestinal flora it has become one of the stakes of pharmaceutical research.
The way to go is not easy because the best bacteria in biota are also the smallest and with less genetic material. Thus, when it comes to cultivating them in the laboratory, they are not capable of growing if it is not with the help of other bacteria with which to link their genetic functions and survive.
Despite this, probiotics are already available in pharmacies that provide approximately a dozen types of bacteria, although in our intestines we harbor about 160 types of these microorganisms.
Thus, an investigation of the Institute of Agrochemistry and Food Technology (IATA), center of the Superior Council of Scientific Investigations (CSIC), has allowed the development of a new generation probiotic that will allow to effectively prevent the metabolic complications of obesity.
The project, funded by the Valencian Innovation Agency (AVI) and where the Technological Institute of the Agrifood Industry (AINIA), consists of the valuation of a bacterium isolated from the intestinal microbiota of lean individuals that is associated with a healthy metabolic phenotype in epidemiological studies.
The studies that have been carried out to date offer promising results because it works through two mechanisms of action. On the one hand, reduces appetite and, on the other, normalizes the immune alterations associated with obesity and that often lead to other chronic diseases, such as type 2 diabetes and cardiovascular pathologies.
Positive health effects
In preclinical trials conducted in an obesity model, administration of the bacteria has been shown to be able to reduce energy intake and body weight and fat, as well as the metabolic alterations associated with obesity, such as hyperglycemia and glucose intolerance, and also reduces intestinal and systemic inflammation that leads to the development of chronic pathologies.
After the first six months of execution, the scientific team has already demonstrated the safety of the bacteria, has raised production to laboratory scale and selected a micro encapsulation system to improve its stability and shelf life.
Eddie is an Australian news reporter with over 9 years in the industry and has published on Forbes and tech crunch.